Skip to main content

Table 1 Summary of patient characteristics

From: A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer

Patient Demographics Gem/Cis Overall Gem/Carbo Overall Gem-]/Cis
Plt Sensitive
Gem/Carbo
Plt Sensitive
Gem/Cis
Plt Resistant
Gem/Carbo
Plt Resistant
  N = 21 N = 27 N = 10 N = 18 N = 10 N = 8
Mean Age [# ± SD (Range)] 61.4
[±10.2(42–84)]
62.0
[+9.1(43–79)]
60.8
[+9.4(49–81)]
60.8
[+8.3(47–79)]
61.6
[+11.9(42–84)]
65.8
[+10.7(43–78)]
Race
 -White 16 20 7 14 8 5
 -Hispanic 3 4 2 3 1 1
 -African American 0 1 0 0 0 1
 -Asian 0 1 0 1 0 0
 -Unreported race 2 0 1 0 1 1
 Mean # of Comorbidities 1.48 1.48 0.70 1.11 2.30 2.50
Tumor Histology
 -Serous 15 17 8 11 6 6
 -Clear Cell 0 1 0 1 0 0
 -Adenocarcinoma 2 2 2 0 0 1
 -Mixed 1 3 0 3 1 1
 -Unreported histology 3 3 0 3 3 0
Tumor Stage
 -I 0 1 0 0 0 1
 -II 2 1 2 0 0 0
 -III 12 17 5 11 6 5
 -IV 3 3 2 3 1 0
 -Unreported stage 4 6 1 4 3 2
Tumor Debulking
 -Optimal (<1 cm) 10 16 5 11 5 4
 -Suboptimal 5 7 2 6 2 1
 -Not a surgical candidate 0 1 0 0 0 1
 -Unreported tumor debulking 6 3 3 1 3 2
 Plt sens/resis/unkn 10/10/1 18/8/1 NA NA NA NA
 Mean # of prior regimens [# ± SD (Range)] 3.5
[+1.7(1–6)]
2
[+1.5(0–6)]
3.2
[+1.5(1–5)]
1.8
[+1.5(0–6)]
4
[+1.9(1–6)]
2.5
[+1.4(1–5)]
  P < 0.003 P < 0.025  
 Mean # of cycles Gem/Plt [# ± SD (Range)] 6.2
[+3.5(1–12)]
5.44
[+2.5(2–12)]
6.7
[+3.5(2–12)]
5.3
[+2.2(2–9)]
5.2
[+3.0(1–9)]
6.3
[+3.0(3–12)]
  1. Abbreviations: Gem-Cis Gemcitabine-cisplatin, Gem-Carbo Gemcitabine-carboplatin, Plt Platinum, SD Standard deviation, sens = sensitive; resis = resistant, unkn = unknown